MicroRNA News and Research

RSS

In genetics, microRNAs (miRNA) are single-stranded RNA molecules of 21-23 nucleotides in length, which regulate gene expression. miRNAs are encoded by genes from whose DNA they are transcribed but miRNAs are not translated into protein (i.e. they are non-coding RNAs); instead each primary transcript (a pri-miRNA) is processed into a short stem-loop structure called a pre-miRNA and finally into a functional miRNA. Mature miRNA molecules are partially complementary to one or more messenger RNA (mRNA) molecules, and their main function is to down-regulate gene expression.

MicroRNAs in breast cancer play a role in development of resistance to tamoxifen

Many breast cancer patients are treated with a drug called tamoxifen. The substance blocks the effect of estrogen and thus suppresses the growth signals of this hormone in cancer cells. When resistance to the drug develops, tumor cells change their growth program: They change their behavior and shape, become more mobile and also adopt the ability to invade surrounding tissue. Scientists working with PD (Associate Professor) Dr. Stefan Wiemann of the German Cancer Research Center (DKFZ) have now also observed these changes in tamoxifen resistant breast cancer cells.

5 May 2012

Alnylam first quarter revenues decrease to $20.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter 2012, and company highlights.

4 May 2012

Mirror-microRNAs control multiple aspects of brain function

Our genes control many aspects of who we are - from the colour of our hair to our vulnerability to certain diseases - but how are the genes, and consequently the proteins they make themselves controlled? Researchers have discovered a new group of molecules which control some of the fundamental processes behind memory function and may hold the key to developing new therapies for treating neurodegenerative diseases.

30 Apr 2012

Heart can regulate energy balance throughout the body

UT Southwestern Medical Center researchers have demonstrated for the first time that the heart can regulate energy balance throughout the body, a finding that may point to more effective treatments for obesity, diabetes, and heart disease.

27 Apr 2012

NEI awards Scripps Research $10.2M grant to develop new treatments for vision disorders

A team led by a scientist from The Scripps Research Institute has been awarded a five-year, $10.2 million grant from the National Eye Institute (NEI) to develop a new type of treatment for diabetic retinopathy, macular degeneration, and other common vision disorders.

23 Apr 2012

APS honors MCW professor with Henry Pickering Bowditch Lecture Award

High blood pressure, or hypertension, is a major problem worldwide, with the latest estimates suggesting that a billion people across the globe may have this condition. Hypertension not only takes an enormous cost on health and wellbeing, but it also exacts an expensive financial toll. Complications from this condition including kidney disease, and its resulting treatments, such as long-term dialysis and kidney transplant, are some of the costliest conditions the American health care system must contend with.

23 Apr 2012

Positive results from Alnylam’s ALN-PCS Phase I trial on severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive results from its Phase I clinical trial of ALN-PCS, an RNAi therapeutic targeting PCSK9 for the treatment of severe hypercholesterolemia.

21 Apr 2012

Developments in mesothelioma treatment presented at 3rd European Lung Cancer Conference

New results presented at 3rd European Lung Cancer Conference in Geneva, Switzerland show important steps being made to improve the diagnosis and treatment of malignant pleural mesothelioma, an aggressive cancer of the outer lining of the lungs caused by asbestos exposure.

19 Apr 2012

Final data from Santaris’ miravirsen Phase 2a trial on HCV to be presented at ILC 2012

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, will present final data from a Phase 2a trial showing that miravirsen given as a four-week monotherapy treatment provided robust dose-dependent anti-viral activity with a mean reduction of 2 to 3 logs from baseline in HCV RNA (log10 IU/mL) that was sustained well beyond the end of therapy.

19 Apr 2012

Study explains why some people develop kidney stones and others do not

Kidney stones strike an estimated 1 million Americans each year, and those who have experienced the excruciating pain say it is among the worst known to man (or woman).

19 Apr 2012

Test can reliably diagnose and monitor brain tumor without the need for surgery

In a breakthrough for the way brain cancer is diagnosed and monitored, a team of researchers, lead by Anna M. Krichevsky, PhD, of the Center of Neurologic Diseases at Brigham and Women's Hospital (BWH) in Boston and Santosh Kesari, MD, PhD, director of Neuro-Oncology at UC San Diego Moores Cancer Center, have demonstrated that brain tumors can be reliably diagnosed and monitored without surgery.

19 Apr 2012

UCSF scientists assemble high-value genetic resource to help researchers

One of the ultimate ways of understanding what impact any particular gene has in human health or disease is to disrupt it-knocking it down or wiping it out in a worm, fly or mouse and gauging what happens next. Now scientists at the University of California, San Francisco (UCSF) Diabetes Center and the Gladstone Institute for Cardiovascular Disease have assembled a large publicly available resource to help researchers determine the importance of genes in mice and better gauge what roles they might play in disease.

17 Apr 2012

Combination treatment shows promise against NSCLC patients ineligible for bevacizumab

A combination of nab-paclitaxel and carboplatin for the treatment of non-small cell lung cancer may be a promising option for patients ineligible for treatment with bevacizumab, according to data presented at the AACR Annual Meeting 2012, held here March 31 - April 4.

4 Apr 2012

NanoString to launch 3 new products for nCounter Analysis System at AACR 2012

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced that it will launch three new products for the nCounter Analysis System at the American Association of Cancer Research (AACR) Annual Meeting 2012, March 31-April 4, in Chicago, Ill.

From NanoString Technologies 31 Mar 2012

State of Texas awards Asuragen $6.8M to pursue Next Generation Sequencing applications

Asuragen, Inc. announced today that the Company received notice of a $6.8 million commercialization award to pursue Next Generation Sequencing (NGS) applications from the State of Texas through the Cancer Prevention and Research Institute of Texas ("CPRIT").

31 Mar 2012

Researchers discover MicroRNAs as new switch of adipose cell development

Hunger has always threatened mankind. This makes it unsurprising that human bodies attempt to store all surplus nourishment in adipose tissue. In developed countries, this life-saving craving is turning into a problem and obesity—adiposity—is turning into a danger. Why, though, does excess fat the body ill? How does fat trigger diabetes? And can these superfluous fat reserves be turned into warmth and just as well burnt?

30 Mar 2012

Avian and swine flu viruses hijack genetic regulators during human infection

Researchers at the University of British Columbia have identified a number of tiny but powerful "genetic regulators" that are hijacked by avian and swine flu viruses during human infection.

29 Mar 2012

MiR-375 regulates IL-13-induced changes in allergic diseases

Researchers have taken a critical step in understanding how allergic reactions occur after identifying a genetic signature for regulation of a key immune hormone, interleukin (IL-13).

29 Mar 2012

MicroRNAs linked to imminent threat of heart attack

Researchers at the Intermountain Medical Center Heart Institute have, for the first time ever, made a connection between tiny genetic molecules called microRNAs and the imminent threat of a heart attack, according to a new study.

26 Mar 2012

Alnylam commences dosing in ALN-TTR02 Phase I clinical trial for TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated dosing in its Phase I clinical trial with ALN-TTR02, an RNAi therapeutic targeting the transthyretin (TTR) gene for the treatment of TTR-mediated amyloidosis (ATTR). The study is aimed at evaluating the safety and tolerability of ALN-TTR02 in healthy volunteers.

19 Mar 2012

MicroRNA News and Research

Further Reading

MicroRNAs in breast cancer play a role in development of resistance to tamoxifen

Alnylam first quarter revenues decrease to $20.6 million

Mirror-microRNAs control multiple aspects of brain function

Heart can regulate energy balance throughout the body

NEI awards Scripps Research $10.2M grant to develop new treatments for vision disorders

APS honors MCW professor with Henry Pickering Bowditch Lecture Award

Positive results from Alnylam’s ALN-PCS Phase I trial on severe hypercholesterolemia

Developments in mesothelioma treatment presented at 3rd European Lung Cancer Conference

Final data from Santaris’ miravirsen Phase 2a trial on HCV to be presented at ILC 2012

Study explains why some people develop kidney stones and others do not

Test can reliably diagnose and monitor brain tumor without the need for surgery

UCSF scientists assemble high-value genetic resource to help researchers

Combination treatment shows promise against NSCLC patients ineligible for bevacizumab

NanoString to launch 3 new products for nCounter Analysis System at AACR 2012

State of Texas awards Asuragen $6.8M to pursue Next Generation Sequencing applications

Researchers discover MicroRNAs as new switch of adipose cell development

Avian and swine flu viruses hijack genetic regulators during human infection

MiR-375 regulates IL-13-induced changes in allergic diseases

MicroRNAs linked to imminent threat of heart attack

Alnylam commences dosing in ALN-TTR02 Phase I clinical trial for TTR-mediated amyloidosis

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News